Mechanism of Xinfeng Capsule on Adjuvant-Induced Arthritis via Analysis of Urinary Metabolomic Profiles
Table 2
Potential biomarkers selected and change of trend in each group.
Number
VarID
Compound
RT
VIP
1
251
2,2-Dimethylsuccinic acid
11.0616
2.70266
0.011313387
0.03490986
0.249996112
2
314
Tartronic acid
11.8754
2.94527
0.024742601
0.15475148
0.010899989
3
636
Dehydroshikimic acid
16.7414
3.05951
0.032774968
0.1022563
0.077357634
4
646
Hippuric acid
16.9083
3.21815
0.01018095
0.19488332
0.049258272
5
684
Adenine
17.5117
2.73672
0.021520896
0.59814266
0.035198717
6
697
Phenaceturic acid
17.7171
4.18817
0.016864462
0.02460963
0.503834004
7
807
L-dopa
19.405
1.31514
0.026524125
0.0252176
0.771814517
8
865
1,4-Dihydroxy-2-naphthoic acid
20.474
3.69942
0.003037716
0.00524929
0.612627294
9
1110
Melibiose
25.9579
2.33593
0.040379626
0.0682718
0.501486543
Note: VarID represents urine screening 1166 peak to the serial number of compound; RT represents retention time of compound. A variable importance in the projection (VIP) was obtained from OPLS-DA model with a threshold of 1.0; represents value by healthy group versus untreated group; represents value by untreated group versus XFC treated group; represents value by XFC treated group versus healthy group.
